Equity Overview
Price & Market Data
Price: $1.59
Daily Change: -$0.0324 / 2.04%
Range: $1.58 - $1.69
Market Cap: $8,910,138
Volume: 11,126
Performance Metrics
1 Week: 5.97%
1 Month: -29.02%
3 Months: -62.14%
6 Months: -61.96%
1 Year: -70.39%
YTD: -51.67%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is APR-1051, which is in Phase 1 clinical trial for treatment of advanced solid tumors with biomarkers that may predict sensitivity to WEE1 inhibition. Its pipeline includes the ATRN-119, an ATR inhibitor that is in a Phase 1/2a clinical trials for treating advanced solid tumors having at least one mutation in a defined panel of DDR-related genes. It also includes an early-stage program, which is in lead optimization stage for an undisclosed DNA-damage response (DDR) target. The company is headquartered in Doylestown, Pennsylvania.